|
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
ABL kinase domain mutations have been implicated in the resistance to the BCR-ABL inhibitor imatinib mesylate of Philadelphia-positive (Ph+) leukemia patients.
|
17189410 |
2006 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
ABL kinase inhibitors have been spectacularly successful in treating CML, but disease persistence and acquired drug resistance can prevent eradication and cure of the leukemia.
|
17353369 |
2007 |
|
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Activation of the abl gene and its involvement in human leukemia is one of the most thoroughly characterized examples of the structural alterations of chromosomes associated with the conversion of a normal cell into a cancer cell.
|
3129652 |
1988 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
As an oral, nontoxic compound with a mechanism of action distinct from that of ABL tyrosine kinase inhibition, FTI SCH66336 shows promise for the treatment of BCR/ABL-induced leukemia.
|
11222387 |
2001 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
As with ABL, translocations that fuse ARG to ETV6/TEL have been identified in patients with leukemia.
|
28386107 |
2017 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Because these two chromosomes are translocated with breakpoints within the BCR and ABL genes in Philadelphia chromosome-positive leukemias, knowledge of these sequences also might provide insight into the validity of various theories of chromosomal rearrangements.
|
7665185 |
1995 |
|
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
CML comprises approximately 20% of all leukemias and is characterized by a balanced (9;22) chromosomal translocation that results in the formation of a chimeric gene comprised of the BCR (breakpoint cluster region) gene and the ABL oncogene (BCR-ABL fusion gene).
|
20300999 |
2010 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Comment on "PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL human leukemia".
|
31316003 |
2019 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with nilotinib against BCR-ABL-positive leukemia cells involves the ABL kinase domain mutation.
|
24100660 |
2014 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Entire ABL gene is joined with 5'-BCR in some patients with Philadelphia-positive leukemia.
|
1868241 |
1991 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Frequent jumping translocations of chromosomal segments involving the ABL oncogene alone or in combination with CD3-MLL genes in secondary leukemias.
|
9002963 |
1997 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, ABL TKIs cannot eradicate leukemia stem cells.
|
27437766 |
2016 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Joining of the BCR and ABL genes is an essential feature of the group of human leukemias characterized by the Philadelphia chromosome and there is recent evidence that the human BCR-ABL fusion gene induces leukemia in experimental animals.
|
1756491 |
1991 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Oligomerization of the ABL tyrosine kinase by the Ets protein TEL in human leukemia.
|
8754809 |
1996 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL<sup>+</sup> human leukemia.
|
29437150 |
2018 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Response to Comment on "PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL<sup>+</sup> human leukemia".
|
31316004 |
2019 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Some oncogene abnormalities are relatively specific for certain leukemias and occur in almost all cases; examples include ABL in chronic myelogenous leukemia or MYC in Burkitt leukemia/lymphoma.
|
2406517 |
1990 |
|
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Specifically, it is associated to a particular cytogenetic abnormality, known as Philadelphia chromosome (Ph), which results from a fusion between part of the BCR ("breakpoint cluster region") gene from chromosome 22 and the Abelson (ABL) gene on chromosome 9 and leads to the formation a new gene leukemia-specific, the BCR-ABL.
|
27281463 |
2016 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The ABL oncogene in human leukemias.
|
3289649 |
1988 |
|
leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The apparent nonrandom contribution of the paternally-derived chromosome 9 and the maternally-derived chromosome 22 to the leukemia-specific translocation t(9;22)(q34;q11) obtained by cytogenetic analysis suggested that the two genes affected by this rearrangement, namely ABL and BCR, are imprinted.
|
7723413 |
1995 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The literature on Ph-positive leukemia lacking ABL exon 2 was also reviewed.
|
18253707 |
2008 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The NEDD8-activating enzyme inhibitor MLN4924 induces DNA damage in Ph+ leukemia and sensitizes for ABL kinase inhibitors.
|
31349760 |
2019 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The Philadelphia translocation, t(9;22), fuses the BCR and ABL genes resulting in the expression of leukemia-specific, chimeric BCR-ABL messenger RNAs.
|
3165197 |
1988 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The significance of the finding that a part of the SH3 region of ABL protein is missing in some Philadelphia chromosome-positive leukemias is discussed in reference to the cases reported previously.
|
7934165 |
1994 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The SRC-ABL inhibitor bosutinib is one of the five tyrosine kinase inhibitors currently approved for the treatment of Philadelphia chromosome-positive leukemias.
|
24490604 |
2014 |